The formation of fat-laden foam cells, which contributes to the fatty streaks in the plaques of atheromas, is an important process in atherosclerosis. 
| INTRODUC TI ON
Atherosclerosis, a kind of chronic arterial disease with high mortality worldwide, is the major cause of acute cardiovascular events. 1 The critical early event in atherosclerosis is the formation of foam cells, which accumulate cytoplasmic lipid droplets (LDs) and can contribute to atherosclerotic plaque rupture and accelerate the development of atherosclerosis. Many studies on atherosclerosis have focused on the role of macrophages, but vascular smooth muscle cells (VSMCs) also contribute to atherosclerotic foam cell formation. [2] [3] [4] [5] A recent study has indicated that nearly three-quarters of foam cells in atherosclerotic plaques are VSMC-derived. 6 Therefore, fully understanding the mechanisms underlying VSMC foam cell formation will help to prevent and treat atherosclerotic disease.
Lipophagy is a conserved cellular process that naturally breaks down intracellular LDs by fusion with lysosomal compartments. 7 Lipophagy was originally identified in hepatic cells, which become a primary site of excessive lipid accumulation in diabetes and related metabolic diseases. 8 Recent studies suggest that compromised degradation of cellular
LDs within body tissues due to a defective lipophagy pathway may play a critical role in lipid stockpile, foam cell production and the rapid development of atherosclerosis. 9 A lipophagy deficiency in macrophages enhances atherosclerotic plaque formation in apoe -/-mice by promoting oxidative stress and stimulating inflammasome activation. 10, 11 Stearoyl-coenzyme A desaturase-1 (SCD1), an integral protein anchored in the endoplasmic reticulum membrane (ER), catalyses the synthesis of primarily oleate, palmitoleate and monounsaturated fatty acids (MUFAs), from palmitate, stearate and saturated fatty acids (SFAs) respectively. 12 SCD1 is involved in regulating diverse cellular processes and functions including inflammation, hormonal signalling, thermogenesis and lipid synthesis and oxidation. 13 Previous studies have shown that SCD1 deficiency attenuated hypertriglyceridemia, hepatic steatosis and insulin resistance in several mouse models of obesity. 14 However, SCD1-deficient mice had atherogenic inflammation and developed larger atherosclerotic lesions. 15 Interestingly, another study reported that SCD1 antisense oligonucleotides significantly reduced the size of atherosclerotic lesions in mice fed a high-cholesterol diet. 16 Moreover, dietary alpha-linolenic acid (ALA) suppressed SCD1 expression, favourably inhibiting cholesterol accumulation and inducing cholesterol efflux in macrophage-derived foam cells. 17 Because of some conflicting results regarding the role of SCD1 in the pathogenesis of atherosclerosis, further studies are needed to establish either a pro-or anti-atherosclerotic role for the desaturase.
Previous studies confirmed the essential function of SCD1 in the regulation of autophagy through the AKT serine/threonine ki- 
| MATERIAL S AND ME THODS

| Experimental protocol
| VSMC proliferation assay
VSMCs were plated in each well of a 96-well plate separately, followed by incubation with 50 μg/mL oxLDL. Cell proliferation rates were detected using a CCK-8 assay kit (Dojindo, CK04).
| VSMC migration assay
VSMCs were seeded in 96-well plates and grown to confluence.
Before incubation with or without oxLDL (50 μg/mL), a standard wound was created with a WoundMaker tool in the monolayer cells.
Plates were scanned with an IncuCyte ZOOM Live-Cell Imaging system (Essen BioScience) at 6 hours intervals and quantified with IncuCyte ZOOM software. 
| TMT-based quantitative proteomic analysis
| Immunocytochemical analysis of VSMCs
VSMCs were incubated with the agents listed in Table S2 , followed by an Alexa Fluor ® 568 secondary antibody (1:100, Thermo Fisher, A10042). Nuclear counterstaining was performed with DAPI Staining Solution (Beyotime, C1005). Confocal images were captured using a Zeiss confocal laser scanning microscope (LSM880). 
| Western blot analysis
Samples (50 μg) were separated by SDS-PAGE and electrotransferred to PVDF membranes. After blocking with 5% non-fat milk for 1 hour at room temperature, membranes were incubated overnight at 4°C with the specific antibodies. The primary antibodies are listed in Table S2 .
The bands were visualized with secondary antibodies and the Luminata Forte Western HRP Substrate (Merck Millipore, WBLUF0500) and densitometry analysis was quantified using ImageJ software. 21 
| Quantitative RT-PCR analysis
qRT-PCR was carried out with the iQ5 Real-Time PCR Detection System. 22 Table S3 provides details regarding the primers used in our study. Relative gene expression was estimated by the 2 −△△Ct method.
| DQ™ Red BSA assay
VSMCs (1 × 10 4 ) were incubated with DQ-BSA (10 μg/mL, Thermo
Fisher, D-12051) 6 hours prior to exposure to 50 μg/mL oxLDL.
Then, the cells were lysed in 1% Triton X-100 in 50 mM Tris-HCL (pH 
| Lysosomal pH measurement
Briefly, VSMCs were grown to 80% confluency in 96-well plates.
LysoSensor Green DND-189 (Thermo Fisher, L7535) was added to each well at 1 μM and incubated for 5 minutes at 37°C. Then, the cells were washed with PBS and run in an Infinite™ M200 Microplate Reader to analyse fluorescence intensity (excitation: 485 and emission: 530). 24 
| SCD1 gene overexpression
Plasmids were transfected into the cells with Lipofectamine 2000
(Invitrogen, 11668019). Twenty-four hours after transfection, the cells were exposed to 50 μg/mL oxLDL for another 48 hours.
pcDNA3.1-SCD1 was designed by Sangon Biotech Corporation and pcDNA3.1 was used as a control.
| Luciferase reporter assays
VSMCs were transfected with the indicated TFEB-responsive plasmid and Renilla plasmid. Twenty-four hours after transfection, cells were exposed to oxLDL and luciferase signals were determined by a dual-luciferase reporter assay kit (Promega, E1980). 
| Cholesterol efflux assay
A cholesterol efflux assay kit (MAK192) was purchased from Sigma.
The effect of SCD1 on cholesterol efflux in VSMCs was examined as in a previous study. 25 
| Statistical analysis
The results are expressed as the mean ± SD. Statistical significance was determined by Student's t test analysis or one-way analysis of variance (ANOVA) (Scheffe's post-hoc test) and P < 0.05 was regarded as significant.
| RE SULTS
| OxLDL induces VSMC proliferation and foam cell formation
OxLDL-induced VSMC proliferation was detected by CCK-8 assay.
As revealed in Figure 1A , exposure to 50 μg/mL oxLDL for 48 hours increased the cell viability in VSMCs. Next, the effect of oxLDLinduced VSMC migration was determined with a wound healing assay. OxLDL at 50 μg/mL did not increase or inhibit the migration of VSMCs compared to the control condition ( Figure 1B) . OxLDL OxLDL tended to increase PLIN2 in a time-dependent manner but not PLIN3 levels ( Figure 1C ). Moreover, BODIPY 493/503 was also applied to examine LDs in oxLDL-loaded VSMCs. Treatment with oxLDL for 48 hours remarkably increased lipid accumulation in VSMCs ( Figure 1D ).
| OxLDL inhibits lipophagy-related gene expression in VSMCs
Cellular LD storage could reflect a balance between LD biogenesis and consumption. 26 Several recent publications have identified proteins including PLIN2, PLIN3, DGAT1, ACAT1, ACAT2, AGPAT1, AGPAT2 and GPAT4 that act in a regulatory way to control LD formation. 27 Interestingly, the genes involved in LD biogenesis showed no significant changes in mRNA expression after oxLDL treatment, except PLIN2 (Figure 2A ). Another suggested mechanism involved in maintaining LD homoeostasis is altered lipolysis. Several genes involved in lipolysis, including ATGL, CGI-58, HSL, LAL and MGL, were tested. 26 However, oxLDL treatment had no significant effect on the genes associated with lipolysis ( Figure 2B ). Cholesterol efflux inhibition contributes to cholesterol accumulation and foam cell formation.
Several genes associated with cholesterol metabolism, including ABCA1, ABCG1, SCARB1 and nCEH, were tested. Here, the level of ABCA1 was decreased in the oxLDL group ( Figure S2A ).
Lipophagy also activates the degradation of cytosolic LDs. 28 One of the key steps in lipophagy involves sequestration of LDs by the autophagosome. LC3 and BECN1 play important roles in double-membrane lipoautophagosome formation, and thus, we detected LC3 and BECN1 expression. Here, a marked decrease in LC3 and BECN1 expression was observed 48 hours after oxLDL exposure ( Figure 2C ). SQSTM1/p62 (sequestosome-1/ p62) protein is an important autophagy receptor for cargo and is efficiently degraded by lipophagy. However, oxLDL had no significant effect on SQSTM1 expression in VSMCs ( Figure 2C ).
To further evaluate autophagic flux, VSMCs were treated with 50 μg/mL oxLDL with or without the specific lysosomal inhibitor chloroquine (CQ). The oxLDL-induced decrease in LC3-II was not significantly enhanced in the presence of CQ ( Figure 2D ).
Taken together, these results suggested that oxLDL decreased lipophagy in VSMCs.
| OxLDL inhibits LD-lysosome fusion in VSMCs
To understand how oxLDL inhibited lipophagy, we first examined lipoautophagosome formation by using anti-LC3 immunostaining and a BODIPY dye together with confocal microscopy. The percentage of lipoautophagosomes was not significantly changed in response to oxLDL treatment ( Figure 3A and 3C) . Inhibiting lipoautophagosome fusion with lysosomes disturbs the LD degradation pathway. To detect whether oxLDL inhibits lipoautophagosome fusion with lysosomes,
we assessed the colocalization of LDs with LAMP2 by confocal microscopy. LDs colocalized well with lysosomes in the control group, but this colocalization was impaired by oxLDL exposure ( Figure 3B and 3D). Collectively, these results showed that the lipophagic flux in oxLDL-exposed VSMCs may be disrupted due to compromised lipoautophagosome fusion with lysosomes. 
| OxLDL inhibits lysosomal biogenesis in VSMCs
The last step of lipophagy is LD degradation with lysosomes and proper lysosome function is essential for recycling LDs. 29 The no- 
| OxLDL inhibits SCD1 expression and disrupts the interaction between SCD1 and LDs in VSMCs
To identify potential proteins involved in oxLDL-inhibited lipophagy, we performed a comparative proteomic analysis of VSMCs treated with oxLDL. A total of 5542 proteins were identified and quantified by proteomic analysis. Compared with those in the control group, 94 proteins displayed statistically significant changes in expression in the oxLDL group, of which 54 proteins were increased and 40 proteins were decreased ( Figure S1 ). The top five proteins that were increased in expression after oxLDL exposure were APO, F I G U R E 2 OxLDL inhibits LD biogenesis and the expression of autophagy-related genes in VSMCs. The VSMCs were treated with 50 μg/mL oxLDL for 0, 12, 24 or 48 h. A and B, The mRNA levels of LD biogenesis genes and lipolysis-related genes were determined. C, The protein levels of LC3, BECN1 and SQSTM1 were quantified by normalization of their density to that of ACTB. Error bars represent SEM, *P < 0.05, **P < 0.01 versus the 0 h group. D, VSMCs were incubated with oxLDL (50 μg/mL) in the absence or presence of CQ (10 μM) for 48 h. The expression of LC3-II was quantified by normalization of its density to that of ACTB. **P < 0.01 versus control group (n = 3) APOB variant, APOB, APOC1 and SAA1, whereas APOD, SCD1, DKK1, PLA2G7 and KERATIN were the top five proteins that were decreased (Table S1 and Figure S1 ). Of these, SCD1 was of great interest because it is essential for autophagy. SCD1 is essential for autophagosome formation and autophagosome-lysosome fusion. 30 Based on a previous study, we postulated that SCD1 is engaged in oxLDL-induced lipophagy in VSMCs. Western blot analysis and RT-PCR showed that the SCD1 levels in the VSMCs were decreased by oxLDL treatment in a time-dependent manner ( Figure 5A-B) .
Moreover, immunofluorescence analysis experiments showed that SCD1 interacted with LDs and this interaction was inhibited by oxLDL, confirming that oxLDL affects not only the expression of SCD1 but also its interaction with LDs ( Figure 5C ).
| Overexpression of SCD1 attenuates oxLDLinduced VSMC proliferation and foam cell formation by increasing lipophagy and cholesterol efflux
Considering the profound impact of SCD1 on lipophagy, we next 
| Overexpression of SCD1 increased TFEB activity
TFEB levels in the VSMCs were dramatically down-regulated by oxLDL exposure (Figure S3A,B) . Luciferase reporter assays also indicated that oxLDL significantly suppressed TFEB transcription activity in VSMCs ( Figure S3C ). Taken together, our results indicated an important role for TFEB signalling in oxLDL-inhibited lipophagy. We F I G U R E 3 OxLDL inhibits LDlysosome fusion in VSMCs. A and C, The colocalization of LC3 puncta and LDs was examined by confocal microscopy in VSMCs treated with oxLDL (50 μg/mL) for 48 h. B and D, Immunofluorescence of VSMCs with anti-LAMP2 antibody and colocalization with LDs after oxLDL (50 μg/mL) for 48 h. *P < 0.05, **P < 0.01 versus control group (n = 3) next examined whether SCD1 overexpression could rescue oxLDLinduced TFEB activity inhibition. In our study, TFEB expression and activity were increased by SCD1 overexpression ( Figure S4A ,B).
More importantly, SCD1 overexpression markedly enhanced TFEB nuclear translocation ( Figure S4C ). LDs are dynamic organelles found in the cytoplasm of almost all eukaryotic cells. 31 LDs vary tremendously in number and size range from 0.1 μm to 100 μm in most cells. 32 LD accumulation is closely associated with human metabolic syndrome including atherosclerosis. 26, 33 Thus, increased levels of LDs can signify either an increase in LD biogenesis or a disruption in the downstream degradation pathway (lipolysis and lipophagy). 34 In our study, oxLDL had no significant effect on LD biogenesis or lipolysis and we postulated that lipophagy impairment may be responsible for the LD accumulation in oxLDL-treated VSMCs. Along with the uncontrolled uptake of oxLDL, impaired cholesterol release and/or excessive cholesterol esterification leads to the accumulation of CE stored in LDs and subsequently triggers the formation of foam cells, which are also of smooth muscle cell origin. In our study, the level of ABCA1, which encodes a transmembrane protein that belongs to the cholesterol reverse transporter family, was decreased in the oxLDL group. Our results suggest that oxLDL also impaired cholesterol efflux and promoted LD accumulation in VSMCs.
| D ISCUSS I ON
F I G U R E 4 OxLDL inhibits lysosomal biogenesis in VSMCs. A, The protein levels of LAMP1 and LAMP2 were quantified by normalization of their density to that of ACTB. B, The mRNA levels of lysosomal biogenesis genes were determined using RT-PCR. C, Lysosomal pH was analysed by LysoSensor Green DND-189 staining. D, Lysosomal protease activity was analysed by DQ-BSA staining. **P < 0.01 versus 0 h group (n = 3)
Autophagy is a highly conserved cellular homoeostatic 'housekeeping' process and it plays a critical role in the clearance of damaged organelles to maintain cell stability and metabolic homoeostasis. 35 47 However, SCD1 inhibition strongly increased susceptibility to atherosclerosis. SCD1 deficiency led to larger atherosclerotic lesions in apolipoprotein B 100 only (ApoB 100/100 ) mice. 48 Moreover, SCD1
achieves an anti-atherogenic effect by promoting reverse cholesterol transport in atherosclerotic diseases. 49 A study has also suggested that repression of SCD1 inhibited macrophage-derived foam cell formation and decreased lipid load in atherosclerotic plaques. The mechanism by which SCD1 inhibition promotes atherosclerosis has not been clearly elucidated. MacDonald et al found that SCD1
plays an important role in suppressing inflammatory responses. 15 Nakaya K et al reported that overexpression of SCD1 enhanced reverse cholesterol transport in macrophages. 49 In our study, the cholesterol efflux assay showed that the SCD1 overexpression group had a higher level of cholesterol efflux to high-density lipoprotein (HDL) than the control group and SCD1 overexpression efficiently increased ABCA1 expression, suggesting that SCD1 also achieves an anti-atherogenic effect by enhancing cholesterol efflux in VSMCs. Our study also showed that SCD1 overexpression dramatically promoted LD-lysosome fusion and increased lysosomal biogenesis. Importantly, our study showed that restoration of lipophagy by SCD1 overexpression was accompanied by the inhibition of foam cell formation, hinting at a prominent role of SCD1-mediated replenishment of lipophagy in alleviating oxLDL-triggered atherosclerosis.
Mechanistically, how SCD1 overexpression increased lipophagy is unclear. Recent findings show that TFEB is a key regulator of lysosomal biogenesis and promotes autophagosomal-lysosomal fusion. 23, 50 Interestingly, TFEB progressively decreased in oxLDL-exposed VSMCs. Notably, SCD1 overexpression promoted TFEB nuclear translocation and enhanced TFEB reporter activity, which demonstrated that the connection between SCD1
(cytoplasm) and TFEB (nuclear) may influence oxLDL-impaired lipophagy.
In summary, our findings give fresh and exciting insight into the communication between oxLDL-induced VSMC foam cell formation and lipophagy signalling, which could contribute to the development of drugs for atherosclerosis that target the SCD1/TFEB signalling pathway. 
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